Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337554 | 1.00 | CNR2 (0.46) | CNR2CNR1MAP3K14THRBCYP2C9 | |
| SCHEMBL1337805 | 0.87 | CNR2 (0.49) | CNR2CNR1CYP2C9GRIA2UGCG | |
| SCHEMBL1337801 | 0.87 | CNR2 (0.49) | CNR2CNR1CYP2C9GRIA2UGCG | |
| SCHEMBL1337818 | 0.80 | TP53 (0.42) | MAP3K14CYP2C9GRIA2UGCG | |
| SCHEMBL1337792 | 0.79 | CNR2 (0.51) | CNR2CNR1GRIA2UGCG | |
| SCHEMBL1337790 | 0.79 | CNR2 (0.51) | CNR2CNR1GRIA2UGCG | |
| SCHEMBL12129738 | 0.74 | CNR2 (0.48) | CNR2CNR1MAP3K14 | |
| SCHEMBL1174975 | 0.73 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL1174976 | 0.73 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL1337512 | 0.72 | RORC (0.40) | CNR2CNR1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653127-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2391627-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | Cara Therapeutics, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2010088050-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885MAP3K14 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.